Trial reportBMC infectious diseases2013
Bioactive glass BAG-S53P4 for the adjunctive treatment of chronic osteomyelitis of the long bones: an in vitro and prospective clinical study.
Trial report in BMC infectious diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 4 syntheses or guidelines pooled it, 114 citations in OpenAlex.
- Clinical Use of S53P4 Bioactive Glass in the Treatment of Bone Defects and Infected Bone: A Systematic Review of the Quality of Clinical Outcomes and A Grade Assessment.Advanced healthcare materials · 2026Pooled it
- A systematic review on bioactive glass as a treatment for limb osteomyelitis and infected nonunion.Bone & joint open · 2025Pooled it
- A systematic review of the single-stage treatment of chronic osteomyelitis.Journal of orthopaedic surgery and research · 2019Pooled it
- Clinical Application of Antimicrobial Bone Graft Substitute in Osteomyelitis Treatment: A Systematic Review of Different Bone Graft Substitutes Available in Clinical Treatment of Osteomyelitis.BioMed research international · 2016Pooled it
- 45S5 bioglass graft decreases surgical site infection after posterior transforaminal lumbar interbody fusion reconstruction compared to alternative graft materials.Journal of spine surgery (Hong Kong) · 2026Article
- Antimicrobial efficacy of 45S5 and borosilicate bioglasses against multidrug-resistant bacteria: an in vitro assay.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Beyond Bioactive Glass Composition: Using Morphology to Improve In Vitro and In Vivo Performance.Advanced healthcare materials · 2025Review
- Antibiotic-Loaded Bioglass 45S5 for the Treatment and Prevention ofPathogens (Basel, Switzerland) · 2025Article
- Surgical treatment of unstable spondylodiscitis with posterior instrumentation and bioactive glass (BAG-S53P4): surgical technique and results at medium-term follow-up.Journal of spine surgery (Hong Kong) · 2025Article
- Antimicrobial Biomaterials Based on Physical and Physicochemical Action.Advanced healthcare materials · 2024Review
- Nano-scaffold-based delivery systems of antimicrobial agents in the treatment of osteomyelitis ; a narrative review.Heliyon · 2024Review
- Quantitative study of early-stage transient bacterial adhesion to bioactive glass and glass ceramics: atomic force microscopic observations.Scientific reports · 2024Article
- Current application and future perspectives of antimicrobial degradable bone substitutes for chronic osteomyelitis.Frontiers in bioengineering and biotechnology · 2024Review
- Use of Autologous Bone Graft with Bioactive Glass as a Bone Substitute in the Treatment of Large-Sized Bone Defects of the Femur and Tibia.Journal of personalized medicine · 2023Article
- Current concepts of bone grafting in trauma surgery.Journal of clinical orthopaedics and trauma · 2023Article
- Additive Manufacturing of Polymer/Bioactive Glass Scaffolds for Regenerative Medicine: A Review.Polymers · 2023Review
- Local Antibiotic Delivery Options in Prosthetic Joint Infection.Antibiotics (Basel, Switzerland) · 2023Review
- Antibiotics in mastoid and epitympanic obliteration with S53P4 bioactive glass: A retrospective study.Laryngoscope investigative otolaryngology · 2022Article
- Comparison of antibacterial and antibiofilm activity of bioactive glass compounds S53P4 and 45S5.BMC microbiology · 2022Article
- Nanotechnology in the Diagnosis and Treatment of Osteomyelitis.Pharmaceutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to explore the in vitro antibacterial activity of the bioglass BAG S53P4 against multi-resistant microorganisms commonly involved in osteomyelitis and to evaluate its use in surgical adjunctive treatment of osteomyelitis.
methodsIn vitro antibacterial activity of BAG-S53P4 against methicillin resistant Staphylococcus aureus and Staphylococcus epidermidis, Pseudomonas aeruginosa and Acinetobacter baumannii isolates was evaluated by means of time kill curves, with colony counts performed after 24, 48 and 72 hours of incubation. In vivo evaluation was performed by prospectively studying a cohort of 27 patients with a clinically and radiologically diagnosed osteomyelitis of the long bones in an observational study. Endpoints were the absence of infection recurrence/persistence at follow-up, no need for further surgery whenever during follow-up and absence of local or systemic side effects connected with the BAG use.
resultsIn vitro tests regarding the antibacterial activity of BAG S53P4 showed a marked bactericidal activity after 24 hrs against all the tested species. This activity continued in the subsequent 24 hrs and no growth was observed for all strains after 72 hrs. Results of the clinical study evidenced no signs of infection in 24 patients (88.9%) at the follow-up, while 2 subjects showed infection recurrence at 6 months from index operation and one more needed further surgical procedures. BAG-S53P4 was generally well tolerated.
conclusionsThe in vitro and in vivo findings reinforce previous observations on the efficacy of BAG-S53P4 for the treatment of chronic osteomyelitis of the long bones, also in the presence of multi-resistant strains and in immunocompromised hosts, without relevant side effects and without the need for locally adding antibiotics.
trial registrationDeutschen Register Klinischer Studien (DRKS) unique identifier: DRKS00005332.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.